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Vascular factors to cognitive impairment in degenerative on nondegenerative diseases have been reported, examined, and debated
for several decades. The various definitions of cognitive impairment
due to vascular origins will make these results diverse. During this
review, we are going to report currently update information of
vascular contributions to cognitive function, in clinical or neuroimaging findings. Risks factors and their managements also will
be discussed and reported to have a comprehensive review.

© The authors 2018. This article is published with
open access at journals.sagepub.com/home/BSA
Creative Commons NonCommercial-NoDerivs
CC BY-NC-ND: This article is distributed under the terms
of the Creative Commons Attribution-NonCommercialNoDerivs 4.0 License (http://www.creativecommons.org/
licenses/by-nc-nd/4.0/) which permits non-commercial use,
reproduction and distribution of the work as published
without adaptation or alteration, without further
permission provided the original work is attributed
as specified on the SAGE and Open Access pages
(https://us.sagepub.com/en-us/nam/open-access-at-sage).

KEYWORDS
Alzheimer’s disease, vascular cognitive impairment,
post stroke dementia, white matter hyperintensity,
diabetic mellitus, hypertension

1

Introduction

Those recognized contribution of vascular factors
to cognitive impairment in degenerative on nondegenerative diseases have been reported and
examined during the last century. In the early 20th
century, progressive loss of cognitive function

in late life was attributed to the narrowing and
stiffness of the arteries accompanied with intracranial hypo-perfusion, and so-called arteriosclerotic dementia.
Among early-onset and late-onset dementia,
Alzheimer disease (AD) pathologically with
neurofibrillary tangles and senile plaques is still
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the most prevalent dementia [1]. In the 1990s,
epidemiologic studies reported associations between stroke risk factors and cognitive impairment,
including dementia, and led to the still-unproven
but existed notion that vascular factors might
promote Alzheimer disease. These complicated
and complex associations are not easy to be
clarified. The pathological and clinical studies
have indicated that the vascular contribution
to AD is still under-estimated because patients
having stroke and dementia were sometimes
considered as vascular dementia but actually
they were AD with cerebral vascular disease or
stroke [2]. Recently, the frequent co-occurrence of
vascular and AD conditions (15% between ages
65 and 89; 30% after age 90 years), suggested
that a multifactorial, rather than dichotomous,
approach to diagnosis and treatment of AD with
vascular lesion may better reflect the realities of
cognitive impairment in elderly population.
Owing to that the diagnostic landscape has
shifted from the clinical history and physically
neurological examination to the advent of
structural imaging, magnetic resonance imaging
(MRI), some studies have reported asymptomatic
white matter hyperintensities (WMH) and silent
brain infarcts (SBI) were discovered on brain
MRI in 20% to 30% of nondemented, community
dwelling, elderly subjects [3]. In other words, the
varied definition of vascular lesion, by clinical presentation, neuroimaging findings, or pathological
examination, make vascular contributions to
cognition blurred and puzzled.

2

Vascular cognitive impairment (VCI)

VCI is a syndrome, clinical status, or phenotype,
not a definite disease. At its simplest, VCI
embodies the concept that cognitive impairment
is caused by vascular origins. The pathways
leading from risk factors to cerebrovascular
disease (CVD) to VCI are widely heterogeneous.

Common sporadic forms of CVD include atherosclerosis, arteriolosclerosis, cerebral ischemic or
hemorrhage infarction, toxic, inflammatory, and
oxidative stress [4].
Moreover, recent consensus committee has
reported the Neuroimaging standards for research
into small vessel disease and its contribution
to ageing and neurodegeneration in which six
categories have reported. Recent small subcortical
infarct, lacune of presumed vascular origin, white
matter hyperintensity (WMH) of presumed
vascular origin, perivascular space, cerebral
microbleed, and brain atrophy are the main
imaging features that contribute to degenerative
disease [5].
Epidemiology
From a public health perspective, VCI is the second
most common cause of cognitive impairment in
late life after AD. The definitions of vascular
dementia (VaD) or VCI so far are not consistent
that the prevalence studies have various reports
according to the definition of VCI or VaD they
used. Some studies have reported 1of 3 persons
meets criteria for dementia after their first
stroke [6]. The prevalence of post-stroke dementia
in the first year after stroke ranges from 7% in
population-based studies of first-ever stroke
excluding pre-stroke dementia to 41% in hospitalbased studies including recurrent stroke and
pre-stroke dementia [7].
Persons with stroke who are not initially
demented are twice as likely as normal controls
to subsequently have dementia over the next 10
years [8]. The risk of post-stroke dementia was
found to be highest in the first months after stroke,
which might partially be due to unrecognized
cognitive impairment before stroke [9]. In other
words, stroke may increase or accelerate the
presentation of possibly underlying degenerated
cognitive impairment.
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After the initial post-stroke incidence of
dementia, the cumulative incidence increases
linearly at a rate of 3% and 1.7% per year in
hospital-based and population-based studies,
respectively [7]. Few studies used long-term
outcomes: the longest observational period was
25 years in a population-based study finding a
cumulative incidence of post-stroke dementia
of 48% at year 25 [10]. The incidence of vascular
dementia increases exponentially after 65 years
of age, ranging from 3 to 19 per 1000 persons per
year at age 80 years [11–13], approximately half
the rate of AD.
Clinical presentation of vascular contribution
to cognitions
VCI has been categorized in many ways including
location (strategic location), clinical presentation
(post stroke cognitive change), or MRI findings
(e.g., small vessels disease).

3

Post stroke dementia (PSD)

In hospital- and community-based series, history
of first stroke doubles the risk of subsequent
dementia [6]. Reported risk factors for dementia
at the time of stroke include lower educational
level, older age, having diabetes mellitus, having
atrial fibrillation, and recurrent stroke [14]. Stroke
locations associated with higher likelihood of
cognitive impairment include left, dominant,
hemisphere, anterior and posterior cerebral artery
distribution, multiple infarcts, and other strategic
infarcts [6]. Neuroimaging variables associated
with post-stroke dementia (PSD) include silent
SBI, WMH, global and medial temporal atrophy,
and others [5, 6]. Concomitant AD is also a major
risk factor for PSD. A recent study has reported
in their cohort, 41 in 72 subjects with cognitive
impairment after stroke/transient ischemic attack
found that those originally with positive amyloid-
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beta deposition detected by Carbon-11-labeled
Pittsburgh compound B Positron Emission
Tomography (C11-PiB PET) after the index event
experienced a more severe and rapid cognitive
decline on the Mini Mental State Examination
(MMSE) and the memory domain of the Montreal
Cognitive Assessment (MoCA) during a 3-year
follow-up compared with those with negative
amyloid PET scans [15]. About 15% to 30% of
persons with PSD have a history of dementia
before stroke [16, 17], and approximately one-third
have significant medial temporal atrophy [18].
Hypothesized paths for post stroke cognitive
decline
Recent consensus committees have hypothesized
the possible 4 clinical paths related to the
cognitive change after stroke in relation to the
original amyloid burden and neuro-inflammatory
status after stroke. Possible trajectories of poststroke cognitive decline:
Trajectory A: In the absence of brain parenchymal β-amyloid deposition, an ischemic infarct
may cause a transient decline in cognitive
function, but full or partial recovery is possible
without further deterioration of cognitive status.
The inflammatory could be transient.
Trajectory B: Similarly, in the absence of brain
parenchymal β-amyloid deposition if vascular
and inflammatory processes trigger ongoing
secondary neuro-degeneration persistently, the
post-stroke cognitive decline occurs.
Trajectory C: In the presence of intra-cranial
amyloid deposition, there is slowly decline in
his cognitive natural although the stroke and its
accompanied transient inflammatory will worsen
the cognition after the stroke. The transient progressed cognitive course will note but eventually
the course is progressing.
Trajectory D: In the presence of deposition of
cerebral amyloid, the ischemic lesion causes a
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loss of cognitive reserve preventing cognitive
recovery, and cognitive decline may even be
accelerated if secondary degeneration is triggered
by persistently inflammatory processes [19].
The hypotheses have been examined in a 3 years
longitudinal VCI study at Hong Kong. Comparing cognitive changes between patients with
and without original beta-amyloid deposition
examined by C-PiB PET, using linear mixed
models and analysis of covariance adjusted for
age and education, those originally with betaamyloid deposition experienced a more severe
and rapid cognitive decline over 3 years after
stroke/transient ischemic attack. Beta-amyloid was
associated with changes in multiple cognitive
domains [15].

4

White matter hyperintensity in AD

White matter hyperintensity in the brain, also
called leukoaraiosis, is frequently observed on
the brain images of older adults. The presence of
WMH has been reported as a useful predictor of
cognitive outcome of AD [20, 21].
Several factors have been examined and
reported to be associated with WMH, in which
peripheral blood inflammatory status, having
hypertension, and age were considered to be
associated with its severity [22]. From genetic
view, evidences from familial and twin studies
supports the hypothesis that genetic factors contribute to the WMH pathogenesis [23] although
no consistent genetic polymorphisms have yet
shown a convincing association with WMH in
these studies [24]. The angiotensin-converting
enzyme (ACE) gene locates on chromosome
17q23 [25] and the ACE gene insertion/deletion
(I/D) polymorphism have been reported to be
associated with ACE protein levels [26]. The
ACE protein can degrade amyloid-β (Aβ) [27]
and ACE activity has a significant influence on
hypertension and inflammatory status [28]. These

results suggest that the ACE I/D polymorphism,
the gene involved in the degradation of Aβ and
the regulation of blood pressure and inflammatory status, might play a vital role in the
pathogenesis of WMH and the clinical course
of AD.
In our study, we have examined 403 patients
clinically diagnosed with AD and we have found
that I allele was associated with a significantly
lower total age-related white matter changes
scale score (ARWMC) compared with the D
allele (4.83 vs 5.93, P = 0.013). The total ARWMC
score was significantly lower for patients with
I/I genotype than those with I/D (4.37 vs 5.87,
P = 0.009) and I/D+D/D genotypes (4.37 vs 5.91,
P = 0.006), after adjustment for age and hypertension. In other words, AD Patients with ACE I/I
genotype are less likely to have WMH, and such
findings are particular prominent in female [29].
The AD patients having ACE I/I genotypes also
will have the more rapidly cognitive worsening
than those with other ACE genotype [29]. These
findings have importantly signified that the
contribution of ACE gene to the cognitive decline
of AD is not relied on only WMH. Importantly
and interestingly in our longitudinal study, we
have found that the WMH will lead to the
cognitive change only more prominent in AD
patients having hypertension, not in all AD. The
ACE gene contribute to the cognitive course of
AD would be pleiotropic [29].

5

Identification and treatment of vascular
factors

The beneficial effects of treating atherosclerotic
risk factors (e.g., hypertension, diabetes mellitus,
and dyslipidemia) for stroke risk reduction are
well established [30]. It has been estimated that
an 8% reduction of vascular risk factors over 10
years would significantly reduce the incidence
of dementia [31].
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5.1

Hypertension: Angiotensin converting
enzyme inhibitor and angiotensin receptor
blocker

protective effect on endothelium and sustains

Midlife hypertension is recognized as the risk

cilostazol has been shown to decrease accu-

factor to develop late-life AD, but not late-life

mulation of Aβ and protect against Aβ-induced

hypertension [32]. These possible mechanisms

cognitive deficits [45]. In our case- control study,

for hypertension to develop dementia are

cilostazole 50 mg twice a day was added in

heterogeneous. In a meta-analysis of several

case group: AD patients with peripheral artery

placebo-controlled trials, treatments of hyperten-

occlusion disease (PAOD) together with their

sion were significantly associated with reduction

original medicine, donepezil 5 mg per day. The

in the combined risk ratio of dementia [33]. The

control group was AD patients without PAOD

Syst-Eur trial [34, 35] suggested that treatment of

treated donepezil 5 mg only. After one year

1000 patients for 5 years could prevent 20 cases

following up, the decline of MMSE score was

of dementia. In progress, a secondary prevention

significantly slow in case group after control

trial among persons with previous stroke or

other variables, age, sex, educational level, and

transient ischemic attack [36], treatment with

apolipoprotein E genotype [40].

blood flow via endothelium independent vasodilatation [43, 44]. In cell line and animal study,

perindopril and indapamide showed a 19%

Another large scale 5 years longitudinally

relative risk reduction in cognitive decline and

observation study also conducted by our team

WMH progression compared to others who did

and has shown that patients initiating cilostazol

not [37]. Retrospective, observational studies

therapy without the prior history of dementia

have suggested the possibility that specific

will have the lower prevalence and incidence of

classes of antihypertensive medications may

having dementia and clinically diagnosed AD.

have differential effects on cognitive outcome.

The samples were identified from “Taiwan’s

For example, several studies have reported

National Health Insurance database” where a

angiotensin-converting enzyme inhibitors and

total of 9148 participants 40 years of age or older

angiotensin receptor blockers were associated with

and free of dementia at baseline were analyzed.

fewer AD condition [38] and less longitudinal

Patients using cilostazol (n = 2287) had a signifi-

cognitive decline [39].

cantly decreased risk of incident dementia com-

5.2 Ischemic stroke: Cilostazole

pared with patients not using that (n = 6861;
adjusted HR (aHR) 0.75; 95% confidence interval

Recently, we have studied and published some

(CI) 0.61–0.92). Moreover, cilostazol use was found

new information for cilostazole in the add-on

to have a significant dose-dependent association

treatment in AD patients to show the secondary

with reduced rate of dementia emergence (p for

benefits of cilostazole preventing cognitive decline

trend = 0.001). Subgroup analysis identified a

apart from its primary stroke prevention [40].

decline of dementia in cilostazol users with

Basically cilostazol is an antiplatelet drug that

diagnosed cerebral vascular disease (aHR 0.34,

inhibits the activity of cyclic adenosine mono-

95% CI 0.21–0.54). These observations suggest

phosphate (cAMP) phosphodiesterase type 3

that cilostazol use may reduce the risk to develop

and is prescribed clinically for the prevention of

dementia, and a high cumulative dose further

cerebral ischemia [41, 42]. It reportedly exerts a

decreases the risk of dementia [46].
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5.3 Type 2 diabetes mellitus (DM): Thiazolidinediones

P = 0.001) in long-term users, and 0.66 (0.49–0.90,

Epidemiological studies have suggested that

study has provided a promising finding that

patients with type 2 diabetes are at an increased

using pioglitazone could be decreased risk of

risk of dementia [47], including Alzheimer disease

having dementia in type 2 DM. The decreased

(AD) and vascular dementia [48]. Many drugs

risk also could be dose-dependent [51].

P = 0.009) in high-mean daily dose users. Our

have been used extensively to treat DM with

6

some secondarily therapeutic benefits.
Thiazolidinediones, agonists of nuclear receptor
peroxisome proliferator-activated receptor gamma
(PPAR-γ), can decrease insulin resistance and
are approved medications for type 2 diabetes
treatment. Secondary benefits apart from glucose
control have been examined. Thiazolidinediones
exert potent anti-inflammatory effects in the
central nervous system and seem to exert neuroprotective effects in vitro [49]. Thiazolidinediones
inhibit Aβ-stimulated proinflammatory responses
and neurotoxicity [50].
In our retrospective study using claims data
from “Taiwan’s National Health Insurance
Research Database”, we have included 6401
patients with type 2 DM treated with pioglitazone
and 12,802 age- and sex-matched patients with

Conclusion

So far, cerebral vascular disease is the second
leading cause of cognitive impairment in late
life. The manifestations of vascular cognitive
impairment are heterogeneous in clinical pictures,
severity, pathophysiology, and also in neuroimaging and biomarkers.
MRI might reveal some evidence of vascular
contribution to cognition such as those small
vessels diseases including WMH, which were
mainly associated with impairment in executive
function. One-third of patients will have poststroke dementia after cerebral stroke and, if not
initially affected, stroke patients are at twice the
risk of subsequent cognitive impairment over
the coming10 years.

type 2 DM too but never treated with piog-

Many risk factors for VCI, such as hypertension,

litazone from 2004 to 2009. Meanwhile, both of

diabetes mellitus, or dyslipidemia are modifiable,

these two groups did not have the diagnoses of

although

dementia at their entrances of the study. After

controlled trials are often inconclusive because

5 years from 2004, 113 (1.8%) and 323 (2.5%)

these intervention modifying these risks are

patients in receiving and not receiving the

often initiated too late, the therapeutic duration

pioglitazone-treated cohorts have developed

is not enough, or the weakness of study design

dementia, respectively. The relative risk of

to provide the possible benefits, if any.

currently

double-blind,

placebo-

dementia decreased by 23% in the pioglitazone-

By and large, the means for early detection

treated cohort compared with that in the

and prevention of VCI are still to be determined

comparison cohort after adjustment for age,

for those heterogeneously unknown and known

sex, hypertension, and stroke (adjusted hazard

factors. The prevention and treatment of VCI

ratio (HR), 0.77; 95% confidence interval (CI) =

could be individualized. The major rescues of

0.62–0.96). In addition, the adjusted HRs (95%

vascular contribution to cognition remain those

CIs) for dementia were 0.50 (0.34–0.75, P = 0.001)

of diligent clinical practice, extensive researches,

in high-cumulative dose users, 0.53 (0.36–0.77,

and public health implementation.
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